Details of the Drug Reposition

General Information of This Drug (ID: DMZQOUX)

Drug Name
Trastuzumab   DMZQOUX
Synonyms Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
Therapeutic Class
Anticancer Agents
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lung cancer DISCM4YA 2C25.0 Approved [1]
Inflammatory breast cancer DIS3QRWA 2C62 Approved [2]
------------------------------------------------------------------------------------
1 Application submitted Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastric adenocarcinoma DISWWLTC 2B72 Application submitted [3]
------------------------------------------------------------------------------------

References

1 Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251.
2 Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)